Swedish Orphan Biovitrum (STO: SOBI) has gained approval from the US Food and Drug Administration for Orfadin (nitisinone) oral suspension to treat hereditary tyrosinaemia type-1 (HT-1), in combination with dietary restriction of tyrosine and phenylanine.
HT-1 is a rare genetic disease that affects infants and children. It can result in liver and kidney complications, and is potentially fatal if untreated. Some 20 years ago, before pharmacological treatment was available, fewer than one third of infants diagnosed with HT-1 before two months of age, lived past their second birthday.
Today, treatment with Orfadin as an adjunct to dietary restriction as well as early diagnosis have improved outcomes for HT-1 patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze